Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Post-Surgical Ocular Inflammation Clear all
Not listed Phase 2 Interventional

Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

NCT00353964
View directory record Official record
Conditions
Ocular Inflammation
Interventions
rEV131, Prenisolone sodium phosphate 1.0%, rEV131 vehicle
Drug
Lead sponsor
Evolutec Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2006 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282
View directory record Official record
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

NCT06164743
View directory record Official record
Conditions
Inflammation
Interventions
VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Inglewood, California • Petaluma, California • Rancho Cordova, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery

NCT01124045
View directory record Official record
Conditions
Cataracts, Inflammation
Interventions
Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
Up to 3 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

NCT04130802
View directory record Official record
Conditions
Inflammation Corneal, Pain, Postoperative
Interventions
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 2, 2026, 4:23 AM EDT
Recruiting Phase 4 Interventional

Dextenza in the Post-op Management of Vitreoretinal Surgeries

NCT04371445
View directory record Official record
Conditions
Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

NCT04089735
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, APP13007, 0.1%, APP13007 Placebo, 0.05%, APP13007 Placebo, 0.1%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 2, 2026, 4:23 AM EDT
Terminated Phase 1 Interventional Results available

A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery

NCT01605942
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone Drug Delivery System, Placebo Drug Delivery System
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intraocular Steroid After Cataract Surgery Study

NCT00478764
View directory record Official record
Conditions
Cataract
Interventions
intraocular triamcinolone and gatifloxicin
Drug
Lead sponsor
Dean Health System
Other
Eligibility
40 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baraboo, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2007 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Not applicable Interventional

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

NCT00405431
View directory record Official record
Conditions
Glaucoma
Interventions
Restasis, Endura (artificial tears)
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 2, 2026, 4:23 AM EDT
Not listed Phase 4 Interventional

Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.

NCT04592081
View directory record Official record
Conditions
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Kerry Assil, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

NCT04739709
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Scottsdale, Arizona • Glendale, California • Hemet, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

NCT04222725
View directory record Official record
Conditions
Post Surgical Ocular Inflammation
Interventions
TRS01 eye drops, Placebo eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Inglewood, California • Petaluma, California • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients

NCT00001311
View directory record Official record
Conditions
Cataracts
Interventions
heparin-surface modified intraocular lens
Device
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

NCT00870103
View directory record Official record
Conditions
Cataract
Interventions
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 2, 2026, 4:23 AM EDT